Agreed, Thig. Looks like the second part of the trial was added. The first part of the trial, ending next month (though it could be ahead of schedule) determined maximum dose. The second part of the trial will be multi-dose, replicating clinical use. This does suggest progress and continued funding by NIH. Good signs!
I agree, Thig, though Sarepta's flu drug would be used primarily in the hospital setting for treating severe cases because it is administered intravenously - at least for now.
There are other exceptions to patent infringement that your Prosensa quote fails to mention. An important one in this case is whether the inventions are, indeed, the same. If not, then no patent infringement. While Sarepta and Prosensa use similar technologies for their exon-skipping drugs, the drugs themselves are distinctly different. Sarepta will prevail in the US patent interference proceeding and in the European appeal.
Thanks for replying to the Nature article and pointing out morpholinos as a therapy. Interestingly, one other commenter mentioned that Ebola cures may already be in our homes: "According to Dr. David S. Fedson, (retired professor of medicine at the University of Virginia), and Dr. Steven M. Opal (a professor of medicine at Brown University), Atorvastatin could possibly cure Ebola Disease." Lipitor (Atorvastatin) is one of the most prescribed drugs in America.
Pasteur, your usual response to someone asking for a source of your statements is to say you are not going to do the DD for them. I will placate your hypocrisy this time. Sarepta issued a press release on February 9, 2012 titled: "Results From Phase I Clinical Trials Demonstrate Positive Safety Data of AVI BioPharma's RNA-Based Therapeutics for Treatment of Ebola and Marburg Viruses". As a result of the demonstrated safety of these two drugs, DSMB recommended going forward with multiple ascending dose studies for both therapeutics.
Go to Espacenet (European Patent Office) and type in Sarepta under worldwide data base. Scroll down to no. 19. There may be others. I haven't checked.
Eugen Uhlmann is the chief science officer and co-founder of AduiTide Pharmaceuticals, in Germany, which bills itself as : "a biopharmaceutical company, which discovers and develops novel nucleic acid-based therapeutics to treat a number of diseases, including cancer, infectious diseases, asthma and allergies, and for use as vaccine adjuvant." Looks like Sarepta has an, as yet, unannounced relationship with AduiTide. I haven't checked the relationships of the other inventors but I suspect they are also with AduiTide Pharmaceuticals.
From Reuters: "Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday." That's scary.
From the Associated Press: "The World Health Organization says the past week has seen the highest increase of Ebola cases since the outbreak began, more evidence that the crisis is worsening."
INHIBITORY OLIGONUCLEOTIDES AND THEIR USE IN THERAPY. July 17, 2014. This appears to be a German patent invented by UHLMANN EUGEN [DE]; JURK MARION [DE]; LEHMANN THOMAS [DE] . I do not recognize these inventors. Background of the invention: Toll-like receptors (TLRs) are present on certain cells of the immune system and have been shown to be involved in the innate immune response. In vertebrates, this family consists of proteins called TLR1 to TLR10, which are known to recognize pathogen associated molecular patterns from bacteria, fungi, parasites, and viruses. TLRs are a key means by which mammals recognize and mount an immune response to foreign molecules and also provide a means by which the innate and adaptive immune responses are linked. TLRs have also been shown to play a role in the pathogenesis of many diseases, including autoimmunity, infectious disease, and inflammation and the regulation of TLR-mediated activation. By using appropriate agents this may provide a means for disease intervention.
Interestingly, I did not find this among those patents filed in the US Patent Office.
When did the twins lose ambulation? Was it by week 1, week 2, or week 5? Week 24 was when the clinical trial results were first reported by Sarepta but the twins may have been lost well before then. Nearly 3 years later, no other children on eteplirsen have lost ambulation.
I wouldn't be surprised to learn that Sarepta tested the assay system and its potential already by providing remaining tissue samples of earlier biopsies to Flagship, comparing its earlier dystrophin findings, and was pleased with the results.
Nigeria’s government has requested experimental drug TKM-Ebola from Vancouver-based Tekmira Pharmaceuticals Corp. (TKMR), Chukwu said. Idris said that as many as three manufacturers of experimental Ebola treatments had been contacted. (Bloomberg).
Sierre Leone's health minister repeated the same caution to his country. "WHO has cautioned us about the risks involved as these drugs have not yet been certified and are still unregistered and untested," he said. Don't expect countries with Ebola concerns to jump at an opportunity to use untested, uncertified drugs.
From World Health Organization (WHO): "Ebola outbreaks have a case fatality rate of up to 90%." That means a survival rate of 10%, Mars2.